This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D56.1 | Synonyms: β-thalassemia, Beta-thalassaemia, Thalassemia major, Thalassemia intermedia, Thalassemia minor
The clinical description of beta thalassemia began in 1925, when Thomas Benton Cooley (1871–1945), a pediatrician in Detroit, USA, first described a syndrome of severe anemia, splenomegaly, and peculiar skeletal deformities in five children from Italian immigrant families. This case report published by Cooley and P. Lee was the first to inform the medical community of the existence of a new anemia syndrome occurring specifically in children of Mediterranean descent. The disease subsequently became widely known as 'Cooley's anemia', after its discoverer.
In 1936, Whipple and Bradford described the pathological features of the disease (bone marrow hyperplasia, attempts at excess red cell production) in more detail. At the same time, as epidemiological evidence accumulated that it occurs at high frequency in Mediterranean countries (Greece, Italy, Cyprus), the name thalassemia, combining the Greek words for 'sea' (thalassa) and 'blood' (haima), became established. Subsequently, with advances in molecular biology in the 1950s–1970s, it became clear that this is not a single disease but a spectrum including several types (alpha, beta).
In 1956, Ingram confirmed through hemoglobin protein sequence analysis that abnormality of the beta-globin chain is central to beta thalassemia. In the 1970s–1980s, researchers including Orkin, Kazazian, and Antonarakis systematically established that various point mutations in the HBB gene (11p15.4) are the molecular cause of beta thalassemia. Subsequently, with advances in molecular cloning and DNA analysis techniques, HBB gene variant databases were built, and more than 300 pathogenic variants have now been reported.
In the 1960s–1970s, regular transfusion became the standard of management for thalassemia major, but transfusional iron overload emerged as a serious complication. With the introduction of iron chelation therapy using subcutaneous deferoxamine in the 1970s, patient survival improved greatly. In 1982, hematopoietic stem cell transplantation (HSCT) was first successfully performed by Thomas and colleagues, and transplant outcomes have improved steadily since, with cure rates for HLA-matched sibling transplants now reaching 80–90%. The FDA approval of the gene therapy betibeglogene autotemcel (Zynteglo) in 2022 and the FDA approval of the CRISPR-based exagamglogene autotemcel (Casgevy) in 2023 opened a new era in the treatment of beta thalassemia.
The cause of beta thalassemia is reduced or absent beta-globin chain synthesis due to various variants of the HBB gene (11p15.4). The HBB gene consists of 3 exons, and variants can occur at various sites, including the promoter, splice sites, and the 5'- and 3'-untranslated regions. More than about 300 pathogenic variants have been reported worldwide, and there are variants that predominate in particular ethnic groups or regions.
HBB variants are classified into two types according to their functional consequence. β0 alleles are variants with no beta-globin synthesis at all (nonsense variants, frameshifts, splicing variants, etc.), and β+ alleles are variants with reduced beta-globin synthesis (promoter variants, mild splicing variants, etc.). β0/β0 homozygosity or β0/β+ compound heterozygosity results in the severe form (thalassemia major), and some β+/β+ cases present as the intermediate form (thalassemia intermedia).
In Mediterranean populations (Italy, Greece, Cyprus), the IVS-I-110 (G>A) splicing variant and the codon 39 (C>T) nonsense variant are common. In South Asians, IVS-I-5 (G>C) and codon 8/9 (+G) frameshift variants are frequent. In Southeast Asians, the codon 41/42 (-TTCT) frameshift and IVS-II-654 (C>T) variants are common. In people of African descent, the -88 (C>T) and -29 (A>G) promoter variants account for a relatively large share.
The HBB gene lies within the beta-globin gene cluster (ε-Gγ-Aγ-δ-β) located on chromosome 11p15.4. The inheritance pattern is autosomal recessive. Heterozygotes (β/β+ or β/β0) have thalassemia minor (trait) with only mild microcytic anemia, and thalassemia major or intermedia is expressed in homozygotes or compound heterozygotes.
| Clinical type | Genotype | Clinical features |
|---|---|---|
| Thalassemia minor (trait) | β/β0 or β/β+ | Mild microcytic anemia, mostly asymptomatic |
| Thalassemia intermedia | β+/β+, β0/β+ (some) | Moderate anemia, occasional transfusion, splenomegaly |
| Thalassemia major | β0/β0, β0/β+ (severe) | Severe anemia at 6 months–1 year of age, transfusion-dependent |
The residual level of fetal hemoglobin (HbF: α2γ2) is a factor that greatly modulates clinical severity. In patients with genetic variants that maintain HbF production into adulthood (e.g., the XmnI-Gγ polymorphism, BCL11A regulatory variants), HbF binds alpha chains and buffers the alpha-chain excess, so the clinical course is milder. BCL11A is a transcription factor that represses HbF and is a key target of gene therapy strategies that inhibit BCL11A.
Beta thalassemia is one of the most common single-gene disorders in the world. About 288 million people worldwide are estimated to be heterozygous carriers (thalassemia minor), and about 60,000–70,000 patients with thalassemia major or intermedia are born each year. According to the WHO, about 1.5% of the world's population are carriers of HBB variants. Carrier frequencies are high in the Mediterranean coast, the Middle East, South Asia, and Southeast Asia. High-frequency areas include Cyprus (14%), Sardinia (8–10%), Greece (7%), Italy (12% in some regions), Iran (5–8%), India and Pakistan (3–8%), and Thailand (5–9%).
Beta thalassemia is very rare in Korea. Its prevalence among people of purely Korean ancestry is extremely low, but with the increase in multicultural families, cases of patients with South Asian and Southeast Asian backgrounds being diagnosed in Korean hematology departments are increasing. Most beta thalassemia patients reported in Korea are second- or third-generation immigrants or children of international couples, and systematic investigation of HBB variants specific to Koreans is limited.
Normal HbA (α2β2) forms stably only when alpha and beta chains are synthesized in equal amounts. When beta-chain synthesis is reduced in beta thalassemia, excess alpha chains accumulate within cells. Excess alpha chains form insoluble aggregates that attach to the cell membrane of red cell precursors (erythroblasts), resulting in ineffective erythropoiesis, in which precursors fail to mature in the bone marrow and are destroyed.
Ineffective erythropoiesis is the core pathology of thalassemia major. The bone marrow becomes hyperplastic to compensate for the red cell deficit, resulting in marrow expansion, skeletal deformities (chipmunk face, skull enlargement), osteoporosis, and pathological fractures. Erythropoietin levels, an indicator of ineffective erythropoiesis, rise extremely, and extramedullary hematopoiesis, including in the liver and spleen, is activated, causing hepatosplenomegaly.
Chronic transfusion and ineffective erythropoiesis itself cause iron overload. Synthesis of hepcidin, which normally suppresses iron absorption, is suppressed by ineffective erythropoiesis, so intestinal iron absorption increases abnormally. Heme iron from transfused red cells is also released as iron during recycling. Excess iron deposits in the heart, liver, pancreas, and endocrine organs, causing cardiomyopathy, liver cirrhosis, diabetes, hypogonadism, and hypothyroidism, respectively.
Thalassemia minor (trait) is mostly asymptomatic, and mild microcytic hypochromic anemia is found on an incidental blood test. Clinical symptoms due to the anemia itself are absent or very mild. Thalassemia intermedia causes moderate anemia (Hb 7–10 g/dL) with fatigue, pallor, and splenomegaly, but survival without transfusion is possible. Iron overload, skeletal deformities, thrombosis, and pulmonary hypertension can develop in adulthood. In thalassemia major, severe anemia appears at around 6 months–1 year of age as maternal HbF disappears. Pallor, jaundice, abdominal distension (splenomegaly), growth failure, fever, and poor appetite are the main symptoms.
In untreated or inadequately managed thalassemia major, skeletal deformities ('chipmunk face': enlarged nasal bones, frontal bossing, enlarged cheekbones), hepatosplenomegaly, and growth failure are prominent. Complications of iron overload include heart failure, liver cirrhosis, diabetes, gonadal failure, and skin pigmentation (bronze diabetes). After splenectomy, the risk of thrombosis and pulmonary hypertension increases. Chronic transfusion-related complications such as alloimmunization and transfusion-transmitted infections can occur.
On physical examination in thalassemia major, the main signs are pallor, jaundice, splenomegaly (sometimes with hepatomegaly), and characteristic facial deformity (chipmunk face). If neglected, splenomegaly progresses to massive splenomegaly, and hypersplenism worsens the cytopenias. Skeletal deformities are characterized by frontal bossing, maxillary enlargement, and broad cheekbones. Growth delay and delayed puberty are also commonly observed.
The complete blood count is characterized by Hb 2–8 g/dL (severe form), markedly decreased MCV and MCH (microcytosis, hypochromia), increased reticulocytes, and the appearance of nucleated red blood cells (nucleated RBC). The peripheral blood smear shows target cells, teardrop cells, nucleated red cells, and anisocytosis. HPLC confirms elevated HbF (10–90% in the severe form), elevated HbA2 (3.5–8% in minor), and decreased or absent HbA. Markedly elevated serum ferritin, serum iron, and transferrin saturation confirm iron overload.
On skull X-ray, the 'hair-on-end' appearance (in which radially arranged trabeculae make the skull look like a brush) is observed as an indicator of bone marrow hyperplasia. Spinal X-ray shows fish vertebrae, and the long bones show cortical thinning. Cardiac MRI T2* imaging is the standard imaging method for assessing cardiac iron overload.
The key to screening for beta thalassemia is prenatal screening before or in early pregnancy. In pregnant women with high-risk ethnic backgrounds (Mediterranean, Middle Eastern, South Asian, Southeast Asian), CBC MCV (<80 fL) and MCH (<27 pg) are used for screening. When microcytosis is present, the HbA2 level is checked by hemoglobin electrophoresis (HPLC). HbA2 ≥3.5% is the typical finding of β-thal trait. Serum ferritin is checked at the same time to exclude iron-deficiency anemia.
When a pregnant woman is identified as having β-thal trait, testing of the partner is essential. When both partners have β-thal trait, prenatal genetic testing is strongly recommended because of the risk (25%) of having a child with thalassemia major.
High-prevalence countries such as Cyprus, Sardinia, Greece, Iran, and Italy have succeeded in reducing the birth rate of thalassemia major by more than 90% through national prevention programs (carrier screening + prenatal diagnosis). In Korea, it is not part of general newborn screening, but identification of high-risk mothers and the prenatal diagnosis system are being gradually strengthened.
HPLC or capillary electrophoresis is the standard method for diagnosing beta thalassemia. HbA2 ≥3.5% is found in thalassemia minor, and HbF 10–90% with markedly decreased or absent HbA in thalassemia major. Iron deficiency should be checked before testing, because in iron deficiency HbA2 may be measured falsely low.
Pathogenic variants are confirmed by Sanger sequencing of the HBB gene or by ethnicity-specific variant panel testing (reverse dot-blot hybridization, ARMS-PCR). After common variants are screened, other variants are identified by sequencing of the entire coding region. Prenatal diagnosis is performed by CVS (at 10–13 weeks of gestation) or amniocentesis (at 15–20 weeks of gestation), and preimplantation genetic testing (PGT-M) is also possible.
Serum ferritin, liver MRI T2* (quantification of iron overload), and cardiac MRI T2* (assessment of cardiac iron overload) are the standard methods for monitoring iron overload. Liver MRI T2* <2.7 ms indicates severe iron overload, and cardiac MRI T2* <20 ms indicates cardiac iron overload.
The standard treatment for thalassemia major is regular transfusion (every 2–4 weeks, target pre-transfusion Hb ≥9–10 g/dL) combined with iron chelation therapy. Iron chelators used are deferoxamine (injection), deferasirox (Exjade/Jadenu, oral), and deferiprone (oral). Deferasirox is the most widely used because of the convenience of once-daily oral dosing, and renal toxicity monitoring is needed. With chronic transfusion dependence, folic acid supplementation and splenectomy (to reduce transfusion requirements) are also used.
Allogeneic hematopoietic stem cell transplantation (allogeneic HSCT) is the curative treatment for beta thalassemia, with long-term survival of 80–90% with HLA-matched sibling donor transplants. Risk stratification according to the Pesaro classification (based on age, hepatomegaly, and adherence to iron chelation) is used to predict transplant outcomes. Unrelated donor transplants, cord blood transplants, and haploidentical HSCT are also increasingly performed.
Luspatercept (Reblozyl) is a fusion protein drug that blocks TGF-β signaling, suppressing ineffective erythropoiesis and promoting mature red cell differentiation. It received FDA approval in 2019 and is given by subcutaneous injection every 3 weeks. Clinical trials have shown that it meaningfully reduces transfusion requirements in patients with thalassemia major and intermedia.
Betibeglogene autotemcel (Zynteglo), which received FDA approval in 2022, is a gene therapy that introduces a functional βA-T87Q globin gene into autologous hematopoietic stem cells using a lentiviral vector. In clinical trials, a substantial proportion of patients with thalassemia major achieved long-term transfusion independence. Exagamglogene autotemcel (Casgevy), which received FDA approval in 2023, is a gene-editing therapy that reactivates HbF by editing the erythroid regulatory element of BCL11A with CRISPR/Cas9.
Thalassemia minor maintains a normal life span without clinically significant complications. The prognosis of thalassemia intermedia is intermediate; patients survive into adulthood with appropriate management but are at risk of complications of iron overload, thrombosis, and pulmonary hypertension. The life expectancy of patients with thalassemia major receiving appropriate transfusion and iron chelation therapy has now been extended into the 40s–50s, but cardiac complications remain the main cause of death.
Advances in iron chelation therapy (deferasirox, deferiprone) have greatly reduced deaths due to cardiac siderosis. Long-term cure is achieved in patients with successful HSCT. In patients who achieve transfusion independence with gene therapy (Zynteglo, Casgevy), quality of life and prognosis are expected to improve greatly.
The prevention strategy successfully implemented in high-prevalence countries consists of ① population-based carrier screening, ② identification of carrier couples, ③ prenatal genetic diagnosis, and ④ termination or treatment of affected pregnancies. In Cyprus, Sardinia, and Greece, this strategy reduced the birth rate of thalassemia major by more than 95%.
In heterozygous carrier couples, there is a 25% chance of a child with thalassemia major in each pregnancy. The fetal genotype is determined by CVS or amniocentesis, and implantation of affected embryos can be prevented through PGT-M.
Adherence to regular transfusion protocols, maintaining adherence to iron chelation therapy, vaccination after splenectomy, regular monitoring of the heart, liver, and endocrine organs, prevention of osteoporosis (vitamin D and calcium supplementation), and prevention of thrombosis are the key strategies for preventing complications.